On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin after surgery, and then as a single agent.
Next CPS. < 1
- Forums
- ASX - By Stock
- IMM
- Merck conundrum
IMM
immutep limited
Add to My Watchlist
0.00%
!
26.5¢

Merck conundrum, page-64
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
26.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $396.3M |
Open | High | Low | Value | Volume |
26.5¢ | 27.0¢ | 26.5¢ | $122.3K | 455.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 323853 | 26.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
27.0¢ | 95074 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 330208 | 0.265 |
21 | 747384 | 0.260 |
10 | 116439 | 0.255 |
22 | 545766 | 0.250 |
8 | 205592 | 0.245 |
Price($) | Vol. | No. |
---|---|---|
0.270 | 89088 | 20 |
0.275 | 156962 | 12 |
0.280 | 174139 | 10 |
0.285 | 141080 | 8 |
0.290 | 156005 | 7 |
Last trade - 14.45pm 31/07/2025 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |